Literature DB >> 29422657

Personalizing Androgen Suppression for Prostate Cancer Using Mathematical Modeling.

Yoshito Hirata1,2, Kai Morino3,4, Koichiro Akakura5, Celestia S Higano6, Kazuyuki Aihara3,4.   

Abstract

Using a dataset of 150 patients treated with intermittent androgen suppression (IAS) through a fixed treatment schedule, we retrospectively designed a personalized treatment schedule mathematically for each patient. We estimated 100 sets of parameter values for each patient by randomly resampling each patient's time points to take into account the uncertainty for observations of prostate specific antigen (PSA). Then, we identified 3 types and classified patients accordingly: in type (i), the relapse, namely the divergence of PSA, can be prevented by IAS; in type (ii), the relapse can be delayed by IAS later than by continuous androgen suppression (CAS); in type (iii) IAS was not beneficial and therefore CAS would have been more appropriate in the long run. Moreover, we obtained a treatment schedule of hormone therapy by minimizing the PSA of 3 years later in the worst case scenario among the 100 parameter sets by searching exhaustively all over the possible treatment schedules. If the most frequent type among 100 sets was type (i), the maximal PSA tended to be kept less than 100 ng/ml longer in IAS than in CAS, while there was no statistical difference for the other cases. Thus, mathematically personalized IAS should be studied prospectively.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29422657      PMCID: PMC5805696          DOI: 10.1038/s41598-018-20788-1

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  32 in total

Review 1.  Mathematical modelling of prostate cancer growth and its application to hormone therapy.

Authors:  Gouhei Tanaka; Yoshito Hirata; S Larry Goldenberg; Nicholas Bruchovsky; Kazuyuki Aihara
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2010-11-13       Impact factor: 4.226

2.  Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression.

Authors:  Celestia Higano; Andrew Shields; Nathanael Wood; Judy Brown; Cathy Tangen
Journal:  Urology       Date:  2004-12       Impact factor: 2.649

3.  Mathematical modeling of prostate cancer progression in response to androgen ablation therapy.

Authors:  Harsh Vardhan Jain; Steven K Clinton; Arvinder Bhinder; Avner Friedman
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-21       Impact factor: 11.205

4.  Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters.

Authors:  Nicholas Bruchovsky; Laurence Klotz; Juanita Crook; Shawn Malone; Charles Ludgate; W James Morris; Martin E Gleave; S Larry Goldenberg
Journal:  Cancer       Date:  2006-07-15       Impact factor: 6.860

Review 5.  Histologic grading of prostate cancer: a perspective.

Authors:  D F Gleason
Journal:  Hum Pathol       Date:  1992-03       Impact factor: 3.466

6.  Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer.

Authors:  G D Grossfeld; U B Chaudhary; D M Reese; P R Carroll; E J Small
Journal:  Urology       Date:  2001-08       Impact factor: 2.649

Review 7.  Mathematically modelling and controlling prostate cancer under intermittent hormone therapy.

Authors:  Yoshito Hirata; Gouhei Tanaka; Nicholas Bruchovsky; Kazuyuki Aihara
Journal:  Asian J Androl       Date:  2012-01-09       Impact factor: 3.285

8.  Intermittent androgen suppression in patients with prostate cancer.

Authors:  A De La Taille; M Zerbib; S Conquy; D Amsellem-Ouazana; N Thiounn; T A Flam; B Debré
Journal:  BJU Int       Date:  2003-01       Impact factor: 5.588

9.  Intermittent versus continuous androgen deprivation in prostate cancer.

Authors:  Maha Hussain; Catherine M Tangen; Donna L Berry; Celestia S Higano; E David Crawford; Glenn Liu; George Wilding; Stephen Prescott; Subramanian Kanaga Sundaram; Eric Jay Small; Nancy Ann Dawson; Bryan J Donnelly; Peter M Venner; Ulka N Vaishampayan; Paul F Schellhammer; David I Quinn; Derek Raghavan; Benjamin Ely; Carol M Moinpour; Nicholas J Vogelzang; Ian M Thompson
Journal:  N Engl J Med       Date:  2013-04-04       Impact factor: 91.245

10.  Predicting disease progression from short biomarker series using expert advice algorithm.

Authors:  Kai Morino; Yoshito Hirata; Ryota Tomioka; Hisashi Kashima; Kenji Yamanishi; Norihiro Hayashi; Shin Egawa; Kazuyuki Aihara
Journal:  Sci Rep       Date:  2015-05-20       Impact factor: 4.379

View more
  6 in total

1.  From Fitting the Average to Fitting the Individual: A Cautionary Tale for Mathematical Modelers.

Authors:  Michael C Luo; Elpiniki Nikolopoulou; Jana L Gevertz
Journal:  Front Oncol       Date:  2022-04-28       Impact factor: 5.738

2.  Opportunities for improving cancer treatment using systems biology.

Authors:  Jason I Griffiths; Adam L Cohen; Veronica Jones; Ravi Salgia; Jeffrey T Chang; Andrea H Bild
Journal:  Curr Opin Syst Biol       Date:  2019-11-27

3.  Modeling the synergistic properties of drugs in hormonal treatment for prostate cancer.

Authors:  Trevor Reckell; Kyle Nguyen; Tin Phan; Sharon Crook; Eric J Kostelich; Yang Kuang
Journal:  J Theor Biol       Date:  2021-01-07       Impact factor: 2.691

4.  Optimal control to reach eco-evolutionary stability in metastatic castrate-resistant prostate cancer.

Authors:  Jessica Cunningham; Frank Thuijsman; Ralf Peeters; Yannick Viossat; Joel Brown; Robert Gatenby; Kateřina Staňková
Journal:  PLoS One       Date:  2020-12-08       Impact factor: 3.240

5.  Quantification and Optimization of Standard-of-Care Therapy to Delay the Emergence of Resistant Bone Metastatic Prostate Cancer.

Authors:  Arturo Araujo; Leah M Cook; Jeremy S Frieling; Winston Tan; John A Copland; Manish Kohli; Shilpa Gupta; Jasreman Dhillon; Julio Pow-Sang; Conor C Lynch; David Basanta
Journal:  Cancers (Basel)       Date:  2021-02-08       Impact factor: 6.639

6.  Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model.

Authors:  Nourridine Siewe; Avner Friedman
Journal:  PLoS One       Date:  2022-01-11       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.